Gilead Sciences

NASDAQ: GILD
Nasdaq Stock Market
Healthcare Drug Manufacturers - General
Global Rank
#79
Country Rank
#63
Market Cap
210.86 B
Price
170
Change (%)
1.44%
Volume
3.09 M

Gilead Sciences's latest marketcap:

210.86 B

As of 11/17/2026, Gilead Sciences's market capitalization has reached $210.86 B. According to our data, Gilead Sciences is the 79th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 210.86 B
Revenue (ttm) 30.99 B
Net Income (ttm) -3,862,000,000
Shares Out 1.24 B
EPS (ttm) -3.12
Forward PE 20.39
Ex-Dividend Date 12/15/2026
Earnings Date 10/29/2026
Market Cap Chart
Data Updated: 11/17/2026

Gilead Sciences's yearly market capitalization.

Gilead Sciences has seen its market value grow from $1.25 B to $210.86 B since 1998, representing a total increase of 16,721.50% and an annual compound growth rate (CAGR) of 20.18%.
Date Market Cap($) Change (%) Global Rank
11/17/2026 $210.86 B 36.9% 79
12/31/2025 $152.28 B 32.28% 124
12/31/2024 $115.12 B 14.04% 137
12/29/2023 $100.94 B -6.25% 141
12/30/2022 $107.68 B 18.22% 121
12/31/2021 $91.08 B 24.72% 172
12/31/2020 $73.03 B -11.17% 197
12/31/2019 $82.21 B 1.6% 129
12/31/2018 $80.92 B -13.53% 104
12/29/2017 $93.58 B -0.81% 99

Company Profile

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a leading biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address unmet medical needs across the United States, Europe, and internationally.

Key Product Offerings

  • HIV/AIDS Treatments: Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla.
  • COVID-19 Treatment: Veklury (intravenous injection).
  • Viral Hepatitis Therapies: Epclusa, Harvoni, Vemlidy, and Viread.
  • Oncology Solutions: Yescarta, Tecartus, and Trodelvy.
  • Other Treatments: Letairis (pulmonary arterial hypertension) and AmBisome (invasive fungal infections).

Strategic Collaborations

Gilead partners with leading organizations to advance medical innovation, including:

  • Arcus Biosciences, Inc.
  • Merck Sharp & Dohme Corp.
  • Galapagos NV
  • Janssen Sciences Ireland Unlimited Company
  • Japan Tobacco, Inc.
  • Dragonfly Therapeutics, Inc.
  • Merus N.V. (for trispecific antibody research)
  • Terray Therapeutics, Inc. (small molecule therapies)
  • LEO Pharma (STAT6 program development)

Founded: 1987 | Headquarters: Foster City, California

Frequently Asked Questions

  • What is Gilead Sciences's (GILD) current market cap?
    As of 11/17/2026, Gilead Sciences (including the parent company, if applicable) has an estimated market capitalization of $210.86 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Gilead Sciences global market capitalization ranking is approximately 79 as of 11/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.